Novartis ESMO Event Presentation

Treatment with Pluvicto had a favorable safety profile and was well tolerated 177 Lu-PSMA-617 ARPI change 63% of patients received 6 cycles of Pluvicto Lower rate of Grade ≥3 AES compared to daily oral ARPI Fewer patients on Pluvicto required a dose adjustment compared to ARPI AE-driven discontinuations were low and balanced between the arms Treatment-related Leading to dose adjustment Leading to discontinuation AES, n (%) (n = 227) (n = 232) Any 223 (98.2) 223 (96.1) Grade 3-4 77 (33.9) 100 (43.1) Serious 46 (20.3) 65 (28.0) Treatment-related 7 (3.1) 5 (2.2) Fatal (Grade 5) 4 (1.8) 5 (2.2) 0 1 (0.4) 8 (3.5) 35 (15.1) 13 (5.7) 12 (5.2) 24 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION NOVARTIS | Reimagining Medicine

View entire presentation